QGEN vs NTRA

For growth investors, Natera, Inc.

(NTRA) is the stronger pick with 35. 9% revenue growth year-over-year, versus 5. 7% for Qiagen N. V. (QGEN). Qiagen N. V. (QGEN) offers the better valuation at 16. 4x trailing P/E (13. 4x forward), making it the more compelling value choice. Analysts rate Natera, Inc. (NTRA) a "Buy" — based on 27 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Natera, Inc.

(NTRA) delivered a total return of +115. 9%, compared to -23. 3% for Qiagen N. V. (QGEN). Over 10 years, the gap is even starker: NTRA returned +20. 9% versus QGEN's +65. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Qiagen N.

V. (QGEN) is the lower-risk stock at 0. 42β versus Natera, Inc. 's 1. 26β — meaning NTRA is approximately 201% more volatile than QGEN relative to the S&P 500. On balance sheet safety, Natera, Inc. (NTRA) carries a lower debt/equity ratio of 13% versus 44% for Qiagen N. V. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Natera, Inc.

(NTRA) is pulling ahead at 35. 9% versus 5. 7% for Qiagen N. V. (QGEN). On earnings-per-share growth, the picture is similar: Qiagen N. V. grew EPS 436. 8% year-over-year, compared to 0. 7% for Natera, Inc.. Over a 3-year CAGR, NTRA leads at 41. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Qiagen N.

V. (QGEN) is the more profitable company, earning 20. 3% net margin versus -9. 0% for Natera, Inc. — meaning it keeps 20. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: QGEN leads at 24. 9% versus -13. 4% for NTRA. At the gross margin level — before operating expenses — NTRA leads at 64. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for QGEN: 41.

7% to $47. 50.

In this comparison, QGEN (0.

8% yield) pays a dividend. NTRA does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Qiagen N.

V. (QGEN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 42), 0. 8% yield). Both have compounded well over 10 years (QGEN: +65. 1%, NTRA: +20. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: QGEN is a small-cap deep-value stock; NTRA is a mid-cap high-growth stock. QGEN pays a dividend while NTRA does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.